microdosing glp 1 alzheimer's Could diabetes and weight loss drugs treat disease? Noom expands its GLP-1 range

Kuno A, Yamada T, Masuda K et al

The trial used an intention-to-treat principle, including all participants who underwent randomization, regardless of their adherence or changes in medication

A Balancing Act: Navigating the GLP-1 Trend January 25, 2024 Diabetes is one of the top trend drivers of pharmacy costs due to the growing diabetic population and newer, more expensive therapies recommended earlier in the treatment plan

International Journal of Endocrinology, 2020 , 7850816

By delineating these pathways, this study seeks to provide a comprehensive knowledge of the intricate interplay between intestinal I/R injury, BBB integrity, and cognitive function, opening the way for potential therapeutic approaches

Merci et trs bientt